Quantcast

Latest Angiogenesis Stories

2014-07-21 20:22:14

CORALVILLE, Iowa, July 21, 2014 /PRNewswire/ -- McCord Research, Inc. was recently granted a second US patent (U.S. Patent No. 8,796,315). This patent describes a method for accelerating wound closure to improve wound healing. According to the inventor, Dr. McCord, this method includes administering or transplanting to individuals who require wound healing, a composition of an effective amount of hydroxytyrosol and oleuropein and cells derived from umbilical cord blood, such that the...

2014-07-10 23:07:39

A form of Vitamin E has been found to block a protein that mesothelioma cells need to form new blood vessels. Raleigh, NC (PRWEB) July 10, 2014 Scientists in Japan say mesothelioma cells respond to an altered form of α-tocotrienol (Vitamin E) by producing less of a protein that helps grow new blood vessels. Surviving Mesothelioma has just posted an article on the new research. Click here to read it now. Researchers at Toyo University’s Graduate School of Life Sciences exposed...

2014-07-07 08:27:35

ROCKVILLE, Md., July 7, 2014 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that its orally-active, Aurora A/angiogenic kinase inhibitor, ENMD-2076, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (HCC). http://photos.prnewswire.com/prnvar/20140706/124566...

2014-06-25 12:29:13

SAN DIEGO, June 25, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (OTCQB: AEMD), the pioneer in creating medical devices that target unmet therapeutic needs in infectious disease and cancer, announced today that the presentation made by Company Chairman and CEO, Jim Joyce at The Wall Street Analyst Forum on June 19(th), is now available at www.aethlonmedical.com. A link to Mr. Joyce's presentation, including both the audio and slide presentation, is accessible at...

2014-06-25 08:31:22

LONDON, June 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Triple Analysis: Melanoma, Angiogenesis and Cancer Vaccineshttp://www.reportbuyer.com/pharma_healthcare/therapeutic/triple_analysis_melanoma_angiogenesis_cancer_vaccines.html This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Each of these three individual parts is evaluated...

2014-06-24 08:32:14

Pioneering Angiogenic Gene Therapy for the Potential Treatment of Millions of Patients with Heart Disease Worldwide SAN DIEGO, June 24, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM) will report today at the Biotechnology Industry Organization's 2014 BIO International Convention on a pre-specified interim analysis from its international ASPIRE Phase 3 registration clinical study of Generx(®) Ad5FGF-4, Cardium Therapeutics' angiogenic gene...

2014-06-20 08:23:08

MUMBAI, June 20, 2014 /PRNewswire/ -- Cytokines, a major group in the protein therapeutics umbrella, are known to be soluble extracellular proteins or glycoproteins which are crucial intercellular regulators, having the capacity to mobilize the cells which are engaged in innate as well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. These proteins are...

2014-06-12 08:30:19

SAN DIEGO, June 12, 2014 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), announced today that Cardium Therapeutics will announce interim results on the Generx(®) angiogenic gene therapy product candidate international ASPIRE Phase 3 registration study at the 2014 BIO International Convention. Hosted by the Biotechnology Industry Organization (BIO), this year's global event for biotechnology will take place June 23-26 at the San Diego Convention Center...

2014-06-11 08:29:11

INDIANAPOLIS, June 11, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the Phase III REACH trial of CYRAMZA(TM) (ramucirumab) in patients with hepatocellular carcinoma, also known as liver cancer, did not meet its primary endpoint; overall survival favored the CYRAMZA arm but was not statistically significant. Encouraging single-agent CYRAMZA activity was observed, with meaningful improvements in key secondary endpoints of progression-free survival, overall...

2014-06-05 12:28:09

Two New Therapies Will Match Progression-Free Survival Improvements Required By Surveyed U.S. Payers for Formulary Inclusion, According to a New Report from Decision Resources Group BURLINGTON, Mass., June 5, 2014 /PRNewswire/ -- Decision Resources Group finds that in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of advanced ovarian cancer (CaO). MOS and disease progression are also key...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related